mmp2 inhibitor i  (Santa Cruz Biotechnology)

Journal: Mediators of inflammation

Article Title: Empagliflozin Reverses Oxidized LDL-Induced RECK Suppression, Cardiotrophin-1 Expression, MMP Activation, and Human Aortic Smooth Muscle Cell Proliferation and Migration.

doi: 10.1155/2023/6112301

Figure Lengend Snippet: FIGURE 2: OxLDL stimulates SMC migration via MMP2 and MMP9 activation. (a, b) OxLDL stimulates MMP2 and MMP9 activation. SMC made quiescent in medium containing ITS-G 1x supplement were exposed to OxLDL or nLDL for 24 hr and then analyzed for MMP2 and

Article Snippet: AR-100, a biphenylsulfonamide and selective inhibitor of MMP2, and AG-L-66085, a cell-permeable and reversible MMP9 inhibitor, were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX).

Techniques: Migration, Activation Assay

Journal: Digestive diseases and sciences

Article Title: Inappropriate Angiogenic Response as a Novel Mechanism of Duodenal Ulceration and Impaired Healing

doi: 10.1007/s10620-011-1753-4

Figure Lengend Snippet: Animal experiment designs

Article Snippet: Groups of unfasted rats were given saline or a selective inhibitor of MMP2 (MMP2 Inhibitor I; EMD Chemicals, Gibbstown, NJ, USA) at 1 mg/rat, s.c. 0.5 h before and 24 h after cysteamine.

Techniques:

Journal: Digestive diseases and sciences

Article Title: Inappropriate Angiogenic Response as a Novel Mechanism of Duodenal Ulceration and Impaired Healing

doi: 10.1007/s10620-011-1753-4

Figure Lengend Snippet: Increased MMP2 and reduced TIMP-1 in duodenal mucosa during duodenal ulceration. Gene expression (a), protein expression (b), concentrations of MMP2 and MMP9 (c), and expression of endogenous MMP inhibitors TIMP-1 and TIMP-2 (d) in rat duodenal mucosa after administration of cysteamine or propionitrile. Ctrl: control. *P < 0.05

Article Snippet: Groups of unfasted rats were given saline or a selective inhibitor of MMP2 (MMP2 Inhibitor I; EMD Chemicals, Gibbstown, NJ, USA) at 1 mg/rat, s.c. 0.5 h before and 24 h after cysteamine.

Techniques: Gene Expression, Expressing, Control

Journal: Digestive diseases and sciences

Article Title: Inappropriate Angiogenic Response as a Novel Mechanism of Duodenal Ulceration and Impaired Healing

doi: 10.1007/s10620-011-1753-4

Figure Lengend Snippet: Proteolytic activity of MMP2 and MMP9 in duodenal ulceration. Up-regulated enzyme activity of MMP2 (a) but not MMP9 (b) measured by zymography in rat duodenal mucosa after administration of cysteamine or propionitrile. Ctrl: control. *P < 0.05

Article Snippet: Groups of unfasted rats were given saline or a selective inhibitor of MMP2 (MMP2 Inhibitor I; EMD Chemicals, Gibbstown, NJ, USA) at 1 mg/rat, s.c. 0.5 h before and 24 h after cysteamine.

Techniques: Activity Assay, Zymography, Control

Journal: Digestive diseases and sciences

Article Title: Inappropriate Angiogenic Response as a Novel Mechanism of Duodenal Ulceration and Impaired Healing

doi: 10.1007/s10620-011-1753-4

Figure Lengend Snippet: Effect of MMP2 inhibition on cysteamine-induced duodenal ulcer and expression of MMP2, TIMP-1, endostatin, and angiostatin. Inhibition of MMP2 by selective MMP2 inhibitor I attenuated cysteamine-induced duodenal ulceration (a), reduced protein expression and proteolytic activity of MMP2 (b), reduced levels of endostatin and angiostatin (c), and increased levels of VEGF (d) and TIMP-1 (e) in duodenal mucosa. *P < 0.05

Article Snippet: Groups of unfasted rats were given saline or a selective inhibitor of MMP2 (MMP2 Inhibitor I; EMD Chemicals, Gibbstown, NJ, USA) at 1 mg/rat, s.c. 0.5 h before and 24 h after cysteamine.

Techniques: Inhibition, Expressing, Activity Assay

Journal: Scientific Reports

Article Title: BMP7 reduces the fibrocartilage chondrocyte phenotype

doi: 10.1038/s41598-021-99096-0

Figure Lengend Snippet: BMP7 increases MMP2 expression and activity in SW1353 cells. ( A ) SW1353 cells (biological triplicates) were exposed to 1 nM BMP7 for 24 h and MMP2 mRNA expression was determined using RT-qPCR analysis. Data were normalized to cyclophillin expression and set relative to control conditions. ( B / C ) In parallel acquired samples with identical treatment (n = 3) MMP2 protein levels and activity in culture supernatant were measured using a MMP2 ELISA and MMP2 activity assay (relative to control condition). ( D ) OA-HACs (n = 18) were exposed to 1 nM BMP7 for 24 h after which MMP2 mRNA expression was measured by RT-qPCR. Data were normalized for cyclophilin mRNA levels and set relative to control conditions per patient. ( E ) SW1353 cells (biological quadruplicates) were pre-incubated with the selective MMP2 inhibitor OA-Hy (50 µM) for 24 h. MMP2 activity was determined and calculated relative to the control condition. ( F ) Collagen type I protein levels were detected in SW1353 cells (biological quintiplicates) by immunocytochemistry in control conditions and conditions exposed to MMP2 inhibitor OA-Hy (50 µM) with and without BMP7. Data were normalized for DNA content and set relative to control conditions. Statistical significance was determined using 2-tailed unpaired Student’s t-tests ( D per donor and as a group). Bars show the mean (± SEM). * P < 0.05, ** P < 0.01, *** P < 0.001 versus control conditions.

Article Snippet: SW1353 chondrosarcoma cells and OA HACs were treated with 1 nM BMP7 (R&D Systems, Minneapolis, MN, USA) for 24 h. Prior to BMP7 exposure, SW1353 cells were pre-incubated for 1 h with 50 μM selective MMP2 Inhibitor I (OA-Hy SantaCruz Biotechnology, Dallas, TX, USA).

Techniques: Expressing, Activity Assay, Quantitative RT-PCR, Control, Enzyme-linked Immunosorbent Assay, Incubation, Immunocytochemistry

Journal: Scientific Reports

Article Title: BMP7 reduces the fibrocartilage chondrocyte phenotype

doi: 10.1038/s41598-021-99096-0

Figure Lengend Snippet: Proposed molecular interactions by which BMP7 attenuates the fibrocartilage chondrocyte phenotype. The potential molecular pathway by which BMP7 attenuates the fibrocartilage chondrocyte phenotype as proposed in this study. Upon BMP7 exposure, chondrocytic cells demonstrate reduced SMAD3 signaling, interfering with PAI1 expression and activity. In addition, following BMP7 exposure, MMP2 expression and activity is increased via PAI1 and MT1-MMP, resulting in a reduced fibrocartilage chondrocyte phenotype. BMP7’s mode of action to reduce chondrocyte fibrosis is MMP2-dependent. Dashed lines: interactions which have been found in organ-fibrosis (with corresponding references), but have not been demonstrated directly in the present study. Solid lines: interactions directly demonstrated in the present study (regarding chondrocyte fibrosis).

Article Snippet: SW1353 chondrosarcoma cells and OA HACs were treated with 1 nM BMP7 (R&D Systems, Minneapolis, MN, USA) for 24 h. Prior to BMP7 exposure, SW1353 cells were pre-incubated for 1 h with 50 μM selective MMP2 Inhibitor I (OA-Hy SantaCruz Biotechnology, Dallas, TX, USA).

Techniques: Expressing, Activity Assay